Key clinical point: Combination ibrutinib, lenalidomide, and rituximab showed manageable safety and positive clinical outcomes in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
Major finding: Among patients in the 20-mg and 25-mg lenalidomide dosing cohorts, no dose-limiting toxicities were observed. Among 39 response-evaluable patients, the overall response rate was 44%.
Study details: A phase 1b study of 45 transplant-ineligible patients with relapsed/refractory DLBCL.
Disclosures: The study was funded by Pharmacyclics. The authors reported financial disclosures related to Pharmacyclics and several other companies.
Goy A et al. Blood. 2019 Jul 22. doi: 10.1182/blood.2018891598